Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
12-dose rifapentine plus isoniazid DOT versus 6 months of isoniazid for latent tuberculosis infection in socially marginalized people
2016-003567-20Phase 4Terminated
- Sponsor
- Aarhus University Hospital
- Start
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in latent tuberculosis infection (LTBI) comparing Rifapentine + isoniazid DOT with Daily isoniazid control (2 arms). Primary endpoint: Treatment adherence / completion. Started Nov 2016; status: terminated.
02
Drugs
rifapentineisoniazid
03
Conditions
latent tuberculosis infection (LTBI)
Beyond the preview
Go deeper on 2016-003567-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003567-20.